The Pharmaceuticals Export Promotion Council of India (Pharmexcil) has laid out an ambitious strategic roadmap for 2026, focusing on value-driven growth, enhanced regulatory capabilities, and diversification into new international markets. The plan was unveiled during the council’s 21st Annual General Meeting (AGM) held on December 29, signalling a pivotal moment in India’s pharmaceutical export journey.
At the AGM, industry leaders highlighted the sector’s ongoing shift from volume-based exports to high-value products, including complex generics, specialty active pharmaceutical ingredients (APIs), and advanced therapeutic platforms. The discussions also underscored the importance of sustainable manufacturing practices, with innovations such as flow chemistry, continuous processing, and green chemistry being recognised as key drivers of quality, regulatory compliance, and global competitiveness.
The council further emphasised empowering micro, small, and medium enterprises (MSMEs), fostering deeper regulatory engagement, and exploring non-traditional markets. The AGM reflected strong momentum and growing confidence in India’s pharmaceutical export ecosystem, positioning it for sustained growth on the global stage.
